ClinicalTrials.gg
Active, not recruitingNCT06625060MERANTIUpdated Sep 8, 2026

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

A Phase 2 interventional study of Corabotase and Placebo in Episodic Migraine and Chronic Migraine, sponsored by Ipsen. Active, not recruiting at 162 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Ipsen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
670
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 696 studies in Migraine Disorders with a site in United States — 93 open to participants now, 115 under way, 27 of them phase 3. Migraine Disorders · United States.

Enrollment
73rd of 609
670 · median 78
Started
2024
with 38 others
Phase 2
90 of 696
7 open now
Primary completion
2027-10
later than 59 of 114 live
Registered
620th of 696
by date

Among the 696 studies in Migraine Disorders with a site in United States, this one is the 73rd largest by enrollment of the 609 interventional ones that give a count, is one of 39 that started in 2024, is one of 90 in phase 2, reaches primary completion later than 59 of the 114 other live ones, and was the 620th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

93 of the 696 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 696 studies in Migraine Disorders with a site in United States, or all of them as a file.
02

Study summary

A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. Corabotase (also known as IPN10200) is a medication that stops the release of these chemical messengers.

Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. "Headache days" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. "Migraine days" occur when the headache displays clear migraine characteristics.

This study aims to determine:

  • The safety and efficacy of injecting Corabotase directly into the muscles of the head and neck to prevent EM and CM,
  • The right amount (dose) of Corabotase to inject at each point,
  • The total amount (dose) of Corabotase that provides the best balance between safety and efficacy preventing migraines.

Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks.

Read the detailed description

The study will consist of 3 periods:

  1. A 'screening period' to assess whether the participant can take part in the study.
  2. Step 1 is divided in two cohorts. The study will assess sequentially the safety of two doses of Corabotase, a lower dose in the cohort 1 and a higher dose in cohort 2. Participants will be administered with the study drug or placebo. The treatment is injected in muscles of the head, face and neck. The safety of participants is monitored throughout the 36 weeks at each cohort.
  3. Step 2: In this step, new eligible participants will be divided into two groups based on their diagnosis (EM or CM). These groups will then be randomly assigned to one of three intervention groups: Dose A, Dose B, or a placebo. The intervention will be given in a series of injections in muscles of the head, face and neck. Participants will be monitored for both efficacy and safety until they complete the Week 36 visit (the end of study).
03

Conditions studied

  • Episodic Migraine
  • Chronic Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICF. Participant has provided written informed consent and signed privacy/data protection documentation;
  2. Male or female ≥18 to 80 years of age at the time of signing the informed consent;
  3. Diagnosis of either EM or CM, per ICHD-3 criteria, for at least 12 months prior to the screening visit;
  4. Diagnosis of migraine at ≤50 years of age;
  5. Participants in the EM group: History of EM diagnosis and headache frequency (i.e. migraine and non-migraine headache): ≤14 headache days in the 4 weeks prior to randomisation on study Day 1 based on information recorded in the eDiary; migraine frequency: ≥6 migraine days in the 4 weeks prior to randomisation on study Day 1 based on information recorded in the eDiary;
  6. Participants in the CM group: History of CM diagnosis and headache frequency (i.e. migraine and non-migraine headache): ≥15 headache days in the 4 weeks prior to randomisation on study Day 1 based on information recorded in the eDiary; migraine frequency: ≥8 migraine days in the 4 weeks prior to randomisation on study Day 1 based on information recorded in the eDiary;
  7. Participant with a history of use of at least one preventive treatment for migraine.

Exclusion criteria

Exclusion Criteria:

  1. History or current diagnosis of migraine with brainstem aura, retinal migraine, complications of migraine, tension-type headache, trigeminal autonomic cephalalgias, hypnic headache, hemicrania continua or new daily persistent headache;
  2. Headache attributed to another disorder (e.g. secondary headaches), except medication overuse headache (MOH);
  3. Current uncontrolled psychiatric or psychological condition, or one that could confound assessment of headaches/migraines or interfere with study participation;
  4. Risk of self-harm or harm to others as evidenced by past suicidal behaviour or endorsing items 3, 4, or 5 on the C-SSRS at screening or Day 1.
  5. Participants presenting with a swallowing disorder of any origin which might be exacerbated by botulinum toxin treatment, such as:

    - Grade 3 or 4 on the Dysphagia Severity Scale (severe dysphagia) with swallowing difficulties and requiring a change in diet.

  6. skin condition or infection that could interfere with injection of study intervention;
  7. Participant has any medical condition or situation that would make them unsuitable for participation in the study;
  8. Participant receiving more than one allowable concomitant migraine preventive treatment;
  9. Known history of an inadequate response to >4 medications prescribed for the prevention of migraine (2 of which have different mechanisms of action to botulinum toxin);
  10. Use of any of the following medications in the specified timeframe prior to the screening visit:

    • Botulinum toxin for migraine within 24 weeks (or for any other medical/aesthetic reason within 16 weeks);
    • Prior use of mAbs blocking CGRP pathway within 12 weeks for preventative treatment of migraine
    • Prior use of oral CGRP receptor antagonist (gepants) for preventative treatment of migraine within 2 weeks;
    • Anaesthetic or injection in any region targeted for treatment with study medication within 4 weeks;
    • Use of cannabidiol or other types of cannabinoids within 30 days;
    • Use of medical device to treat migraine within 4 weeks (e.g. non-invasive neuromodulation therapies such as nerve stimulation (gammaCore), transcranial magnetic stimulation (cephaly), external trigeminal nerve stimulation, transcutaneous electrical nerve stimulation and peripheral neuroelectrical stimulation);
    • Use of other intervention to treat migraine that is assessed to interfere with study evaluations within 4 weeks (e.g. acupuncture in the head and neck region, cranial traction, nociceptive trigeminal inhibition, occipital nerve block treatments and dental splints for headache);
    • Use of opioids or barbiturates for more than 2 days/month within the last 4 weeks.
  11. Concurrent participation in another interventional clinical study (or within specified timeframe according to national or local legislation or requirements);
  12. Diagnosis of other significant pain disorders that could confound the assessment of headaches/migraines or interfere with study participation, including but not limited to chronic pain disorders such as fibromyalgia, chronic low back pain and complex regional pain syndrome;
  13. Pregnant women, nursing women, premenopausal women, or (i.e. not surgically sterile or 1 year ) not willing to practice an acceptable method, at the beginning of the study and for a minimum of 12 weeks following the administration of study treatment;
  14. Male subjects who are not vasectomised and who have female partners of childbearing potential and are not willing to use condoms with spermicide for a minimum of 12 weeks following the initial double-blind administration of the treatment;
  15. History of alcohol or drug abuse within 5 years of the screening visit (excluding medication overuse for headache);
  16. (BMI) ≥35 kg/m² at the screening visit;
  17. Known clinically significant to any of the study drugs, or materials used to administer the study drug;
  18. Patients who, in the clinician's judgment, are actively suicidal, and therefore, deemed to be at significant risk for suicide.
  19. A diagnosis of a neuromuscular disorder or respiratory disorder, such as myasthenia gravis, Lambert-Eaton syndrome or amyotrophic lateral sclerosis that in the opinion of the investigator would compromise the safety of the study participant.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
670 participants (actual)

Study arms

  • Experimental
    Step 1 - Cohort 1- Corabotase

    Participants will receive Corabotase dose A through injections at Day 1.

    Biological: Corabotase

  • Placebo comparator
    Step 1 - Cohort 1 - Placebo

    Participants will receive placebo through injections at Day 1.

    Other: Placebo

  • Experimental
    Step 1 - Cohort 2 - Corabotase

    Participants will receive Corabotase dose B through injections at Day 1.

    Biological: Corabotase

  • Placebo comparator
    Step 1 - Cohort 2 - Placebo

    Participants will receive placebo through injections at Day 1.

    Other: Placebo

  • Experimental
    Step 2- EM group Corabotase Dose A

    Dose A will be administered to the participants in a single treatment cycle.

    Biological: Corabotase dose A

  • Experimental
    Step 2- EM group Corabotase Dose B

    Dose B will be administered to the participants in a single treatment cycle

    Biological: Corabotase dose B

  • Placebo comparator
    Step 2- EM group placebo

    Placebo will be administered to the participants in a single treatment cycle

    Other: Placebo

  • Experimental
    Step 2- CM group Corabotase Dose A

    Dose A will be administered to the participants in a single treatment cycle

    Biological: Corabotase dose A

  • Experimental
    Step 2- CM group Corabotase Dose B

    Dose B will be administered to the participants in a single treatment cycle

    Biological: Corabotase dose B

  • Placebo comparator
    Step 2- CM group placebo

    Placebo will be administered to the participants in a single treatment cycle

    Other: Placebo

Interventions

  • BiologicalCorabotase

    Lyophilised powder

  • OtherPlacebo

    Excipients without active substance, Lyophilised powder

  • BiologicalCorabotase dose A

    Lyophilised powder

  • BiologicalCorabotase dose B

    Lyophilised powder

06

What researchers measure

Primary outcomes

  1. Percentage of participants experiencing any Adverse Event (AEs) including treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse event of special interest (AESI) and AE leading to treatment discontinuation

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is an AE for which the start date is on or after the date that the intervention began.

    Time frame: For step 1: From baseline until end of study at Week 36

  2. Percentage of Participants with clinically significant changes from baseline in Laboratory Parameters

    Clinically significant change in laboratory parameters will be reported. The clinical significance will graded by the investigator.

    Time frame: For step 1: At all timepoints post injection until Week 36

  3. Percentage of Participants With Clinically Significant Changes from baseline in Vital Signs

    Clinically significant changes in vital signs will be reported. The clinical significance will be graded by the investigator.

    Time frame: For step 1: At all timepoints post injection until Week 36

  4. Percentage of participants with clinically significant change from baseline in facial examination

    Clinically significant changes in facial examination and focused neurological/physical examinations will be reported. The clinical significance will be graded by the investigator.

    Time frame: For step 1: At all timepoints post injection until Week 36

  5. Percentage of participants with clinically significant change from baseline in 12-lead Electrocardiogram (ECG) readings

    Time frame: For step 1: At all timepoints post injection until Week 36

  6. Treatment-emergence of suicidal ideation/suicidal behaviour

    It will be assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) questionnaire that consists of 2 subscales: 1. Ideation severity subscale: questions answered yes/no, severity of ideation scored 1-5 with 5 being most severe 2. Intensity of ideation subscale : scores range from 2-25 with higher scores indicating more severe intensity of ideation.

    Time frame: For step 1: At all timepoints post injection until Week 36

  7. Percentage of participants with Binding antibodies to IPN10200

    Time frame: For step 1: At baseline, Week 4, Week 12 and Week 36.

  8. Percentage of participants with neutralising antibodies to IPN10200

    Time frame: For step 1: At baseline, Week 4, Week 12 and Week 36.

  9. Change from baseline in the number of Monthly migraine days (MMD)s

    Time frame: For step 2: At Week 12 (Weeks 9-12).

Secondary outcomes

  1. Change from baseline in the number of MMD

    Time frame: For Step 1 and step 2: From Week 1 to Week 36.

  2. Change from baseline in the number of Monthly Headache Days (MHD)

    Time frame: For Step 1 and step 2: From Week 1 to Week 36

  3. Change from baseline in the number of moderate/severe MHD

    Time frame: For Step 1 and step 2: From Week 1 to Week 36

  4. Migraine prevention response

    Migraine prevention response is assessed using two thresholds: by a reduction from baseline of either ≥50% or ≥75% in MMD

    Time frame: For Step 1 and step 2: From Week 1 to Week 36

  5. Headache prevention response

    Assessed using two thresholds: by a reduction from baseline of either ≥50% or ≥ 75% in MHD

    Time frame: For Step 1 and step 2: From Week 1 to Week 36.

  6. Change from baseline in the number of days per 4 week period of acute medication use for migraine relief.

    An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) for the acute treatment of migraine.

    Time frame: For Step 1 and step 2: From Week 1 to Week 36.

  7. The use of acute migraine medication (yes or no)

    The use of acute migraine medication will be recorded in the daily eDiary.

    Time frame: For Step 1 and step 2: From Week 1 to Week 36.

  8. Percentage of participants with Binding antibodies to IPN10200

    Time frame: For step 2 : At baseline, Week 4, Week 12 , Week 24 and Week 36.

  9. Percentage of participants with neutralising antibodies to IPN10200

    Time frame: For step 2 : At baseline, Week 4, Week 12 , Week 24 and Week 36.

07

Study locations

162 sites

Showing the first 100 of 162 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 36 months is above that.

Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 3, 2024
StartActual
Oct 10, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06625060
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Oct 10, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Corabotase

Start the discussion